Hudson Institute partner BiomeBank has secured a multimillion-dollar Federal Government grant that will turbocharge the development and production of microbiome-based therapeutics.
The Adelaide-based biotech company has received a grant of $2,147,887 from the Australian Government Cooperative Research Centres Projects (CRC-P) to develop a manufacturing facility for cultured microbial therapeutics.
The project is a collaborative partnership between BiomeBank, Hudson Institute of Medical Research and Cytiva.
With a budget of $5.7 million over the next three years the project aims to create the infrastructure and ‘know-how’ to scale the new microbial therapies being developed by BiomeBank to commercially viable volumes.
Microbiome therapeutics – a new frontier in medicine
The global microbial therapeutic market is projected to reach a valuation of $45 billion by 2030, making the gut microbiome a new frontier in medicine.
, who leads a research at Hudson Institute, says the project is an exciting step towards building capacity across the industry in Australia.
Improved understanding of the human microbiome and recent technological advances provide an opportunity to develop a new generation of therapies. We’re excited to continue our longstanding collaborative partnership with BiomeBank, which has already proven itself as a world-leader by achieving the first regulatory approval of a microbiome therapy worldwide. Associate Professor Sam Forster
This is another example of the how the team at Hudson are delivering, in collaboration with our commercial partners, advancing the translation of discovery research outcomes, generated at the Institute, targeting new products and services for patients.
About BiomeBank
is a clinical stage biotechnology company developing a pipeline of microbiome-based therapies to treat unmet medical need. BiomeBank’s mission is to treat and prevent disease by restoring gut microbial ecology. BiomeBank was founded in 2018 by gastroenterologists Dr Sam Costello, Assoc Prof Rob Bryant, infectious diseases physician Dr Emily Tucker and microbiome scientist Assoc Prof Sam Forster in collaboration with The Hospital Research Foundation with the aim of commercialising the first donor derived microbiome therapy in the world and developing a cultured, scalable version of a healthy human gut microbiota. Backed by a world-leading team of translational microbiome experts, BiomeBank’s platform uses a unique combination of machine learning and microbiology to identify bacterial strains which influence disease, leading to the discovery and development of new therapies.
About Cytiva
At Cytiva, our mission is to advance and accelerate the development of therapeutics. With nearly 15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma, and contract manufacturers. Learn more at cytiva.com.
